A study of new drug approval pattern of a Southeast Asian developed country from 2017 to 2021

Nilesh Chavda; Nirav Patel; Jatin V Dhanani; Priti Solanky

doi:10.5455/njppp.2023.13.06289202220062022

2023, Vol: 13, Issue: 3

13/3Current Issue Online First Archive Aims and Scope Abstracting & Indexing Most Accessed Articles Most Downloaded Articles Most Cited Articles

Required files to be uploaded

Authorship Declaration

« Previous Article

Original Research

Natl J Physiol Pharm Pharmacol. 2023; 13(2): 267-273

doi: 10.5455/njppp.2023.13.06289202220062022

A study of new drug approval pattern of a Southeast Asian developed country from 2017 to 2021

Nilesh Chavda, Nirav Patel, Jatin V Dhanani, Priti Solanky.

Abstract
Background: The pattern of new drug approval is changing across the world as shown by the study using Center for Drug Evaluation and Research and European Medicines Agency data in US and UK with more drug approval for anti-cancer and immunomodulator drugs. There is a need to generate similar database for developed South East Asian countries too.

Aims and Objectives: This study was conducted for one such country- Singapore for the new drug approval pattern of last 5 years (2017–2021).

Materials and Methods: This was a pharmacoepidemiological study, in which government drug regulatory website data available in public domain was searched. The new drug approval data were classified according to active ingredient, drug approval date, new drug application category, indication of drugs, and World Health Organization Anatomic Thoracic Classification.

Results: In this study, 418 new drug approvals were found in last 5 years in Singapore. From this maximum, drug approvals were given to anti-neoplastic and immunomodulator category drugs. In anti-neoplastic category new drugs approval few examples were Trastuzumab deruxtecan and Tucatinib for breast cancer therapy and Tepotinib and Capmatinib for non-small cell lung cancer therapy.

Conclusion: This study shows that drug development in anti-cancer drug and immunomodulator is significant in Singapore. This trend is quite matching with other country such as US and UK.

Key words: New Drug Approval; Singapore; Health Science Authority

	ARTICLE TOOLS
	Abstract
	PDF Fulltext
	How to cite this article
	Citation Tools
	Related Records
	Articles by Nilesh Chavda Articles by Nirav Patel Articles by Jatin V Dhanani Articles by Priti Solanky
	on Google
	on Google Scholar

How to Cite this Article

Pubmed Style

Chavda N, Patel N, Dhanani JV, Solanky P. A study of new drug approval pattern of a Southeast Asian developed country from 2017 to 2021. Natl J Physiol Pharm Pharmacol. 2023; 13(2): 267-273. doi:10.5455/njppp.2023.13.06289202220062022

Web Style

Chavda N, Patel N, Dhanani JV, Solanky P. A study of new drug approval pattern of a Southeast Asian developed country from 2017 to 2021. https://www.njppp.com/?mno=48773 [Access: March 01, 2023]. doi:10.5455/njppp.2023.13.06289202220062022

AMA (American Medical Association) Style

Chavda N, Patel N, Dhanani JV, Solanky P. A study of new drug approval pattern of a Southeast Asian developed country from 2017 to 2021. Natl J Physiol Pharm Pharmacol. 2023; 13(2): 267-273. doi:10.5455/njppp.2023.13.06289202220062022

Vancouver/ICMJE Style

Chavda N, Patel N, Dhanani JV, Solanky P. A study of new drug approval pattern of a Southeast Asian developed country from 2017 to 2021. Natl J Physiol Pharm Pharmacol. (2023), [cited March 01, 2023]; 13(2): 267-273. doi:10.5455/njppp.2023.13.06289202220062022

Harvard Style

Chavda, N., Patel, . N., Dhanani, . J. V. & Solanky, . P. (2023) A study of new drug approval pattern of a Southeast Asian developed country from 2017 to 2021. Natl J Physiol Pharm Pharmacol, 13 (2), 267-273. doi:10.5455/njppp.2023.13.06289202220062022

Turabian Style

Chavda, Nilesh, Nirav Patel, Jatin V Dhanani, and Priti Solanky. 2023. A study of new drug approval pattern of a Southeast Asian developed country from 2017 to 2021. National Journal of Physiology, Pharmacy and Pharmacology, 13 (2), 267-273. doi:10.5455/njppp.2023.13.06289202220062022

Chicago Style

Chavda, Nilesh, Nirav Patel, Jatin V Dhanani, and Priti Solanky. "A study of new drug approval pattern of a Southeast Asian developed country from 2017 to 2021." National Journal of Physiology, Pharmacy and Pharmacology 13 (2023), 267-273. doi:10.5455/njppp.2023.13.06289202220062022

MLA (The Modern Language Association) Style

Chavda, Nilesh, Nirav Patel, Jatin V Dhanani, and Priti Solanky. "A study of new drug approval pattern of a Southeast Asian developed country from 2017 to 2021." National Journal of Physiology, Pharmacy and Pharmacology 13.2 (2023), 267-273. Print. doi:10.5455/njppp.2023.13.06289202220062022

APA (American Psychological Association) Style

Chavda, N., Patel, . N., Dhanani, . J. V. & Solanky, . P. (2023) A study of new drug approval pattern of a Southeast Asian developed country from 2017 to 2021. National Journal of Physiology, Pharmacy and Pharmacology, 13 (2), 267-273. doi:10.5455/njppp.2023.13.06289202220062022

Author Login Reviewer Login About Publisher Editorial Policies Peer Review Policy Editorial & Peer Review Process Publication Ethics and Publication Malpractice Statement Conflict of Interest Policy Plagiarism Policy Protection of Research Participants (Statement On Human And Animal Rights)Corrections, Retractions & Expressions of Concern Self-Archiving Policies Statement of Informed Consent Advertising Policy Terms of Use License Information Copyright Information



Copyright © 2023 National Journal of Physiology, Pharmacy and Pharmacology All Rights Reserved. Subject to change without notice from or liability to National Journal of Physiology, Pharmacy and Pharmacology. For best results, please use Internet Explorer or Google Chrome	Contact Information Publisher publishernjppp@gmail.com Editorial query editornjppp1@gmail.com MOB - 8780040272

Contact Information

How to cite this article